脑下深层大脑刺激减轻了在帕金森病中步态序列效应和步态结
Chuyi Cui1, Goun Je2, Kevin B Wilkins1
1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, United States.
Parkinsonism & related disorders
|September 24, 2025
概括
序列效应,在帕金森病 (PD) 中的一个步态问题,加剧了步态结 (FOG). 脑下核深度大脑刺激 (STN-DBS) 有效地降低了这种效应,并改善了PD患者的FOG.
科学领域:
- 神经科学是一个神经科学.
- 运动障碍 运动障碍
- 步态分析 步态分析
背景情况:
- 序列效应的特征是渐进的步伐缩短,在帕金森病 (PD) 中显著导致步态结 (FOG).
- 这种效应对多巴胺类药物和注意力策略等常规治疗方法具有抗性,突出显示了对替代干预措施的需求.
- 脑下核深脑刺激 (STN-DBS) 是一种常见的PD疗法,但其对步态和FOG的影响仍在调查中.
研究的目的:
- 在患有PD的个体中量化评估空间时空步态参数中的序列效应.
- 确定STN-DBS在减轻序列效应及其相关FOG症状方面的有效性.
主要方法:
- 十八名双边STN-DBS的PD患者和十四名健康对照人进行了步入位置任务以诱导FOG.
- 使用腿部IMU传感器记录了行走动力学,PD参与者被评估为OFF和ON STN-DBS (没有药物).
- 分析了序列效应,将指数式衰变函数应用于结事件之前的步态参数.
主要成果:
- 序列效应在PD患者中观察到,而不是对照组,表现为减小的摆动角速度和范围.
- 在序列效应的严重程度和结治疗所花费时间的百分比之间发现了显著的相关性 (p < 0.001).
- STN-DBS显著降低了序列效应 (p = 0.002) 并减少了结事件 (p = 0.01).
结论:
- 步入位置任务有效地证明了PD中的序列效应,表明步态恶化有助于FOG.
- STN-DBS在缓解序列效应方面被证明是有效的,导致FOG严重程度的降低.
- 这些发现支持STN-DBS作为改善步态和减少帕金森病FOG的治疗选择.
相关概念视频
Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


